Related references
Note: Only part of the references are listed.Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results
Peter J. Hoskin et al.
RADIOTHERAPY AND ONCOLOGY (2021)
Safety and Efficacy of Ultra-hypofractionation in Node-positive Prostate Cancer
T. Telkhade et al.
CLINICAL ONCOLOGY (2021)
Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery
Matthias Guckenberger et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2020)
Technological quality requirements for stereotactic radiotherapy Expert review group consensus from the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy
Daniela Schmitt et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2020)
Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results
Thomas Zilli et al.
CANCER MEDICINE (2020)
Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer
Sagar A. Patel et al.
RADIATION ONCOLOGY (2020)
Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial
Luke Nicholls et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2020)
Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies
William C. Jackson et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Prostate Cancer, Version 2.2019
James L. Mohler et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
Anders Widmark et al.
LANCET (2019)
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
Douglas H. Brand et al.
LANCET ONCOLOGY (2019)
Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial
Thomas Zilli et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer
Michael J. Zelefsky et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)
David Dearnaley et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation
Yasir Alayed et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis
Laura Callan et al.
ADVANCES IN RADIATION ONCOLOGY (2019)
Early Results of Extreme Hypofractionation Using Stereotactic Body Radiation Therapy for High-risk, Very High-risk and Node-positive Prostate Cancer
V. Murthy et al.
CLINICAL ONCOLOGY (2018)
Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life
Hima Bindu Musunuru et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?
Alejandro Gonzalez-Motta et al.
PRACTICAL RADIATION ONCOLOGY (2018)
Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: Preliminary Toxicity Results of a Phase 2 Trial
A. U. Kishan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
W. James Morris et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Management of high-risk prostate cancer with 5-treatment stereotactic body radiotherapy: Long-term results.
Josephine Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
Charles N. Catton et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The Role of Hypofractionated Radiotherapy in Prostate Cancer
Linus C. Benjamin et al.
CURRENT ONCOLOGY REPORTS (2017)
American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer
Daniel E. Spratt et al.
BRACHYTHERAPY (2017)
First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life
Ashutosh Dixit et al.
JOURNAL OF MEDICAL RADIATION SCIENCES (2017)
Hypofractionated stereotactic body radiotherapy for localized prostate cancer - first Nordic clinical experience
Kristiina Koskela et al.
ACTA ONCOLOGICA (2017)
High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients
A. Pontoriero et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2016)
Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes
Rupesh Kotecha et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Risk Stratification for Intermediate- and High-Risk Patients
A. Katz et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
W. Robert Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial
Luca Incrocci et al.
LANCET ONCOLOGY (2016)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David Dearnaley et al.
LANCET ONCOLOGY (2016)
The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups
Anthony Ricco et al.
FRONTIERS IN ONCOLOGY (2016)
Predicting Biochemical Disease-Free survival after Prostate stereotactic Body radiotherapy: risk-stratification and Patterns of Failure
Alan Katz et al.
FRONTIERS IN ONCOLOGY (2016)
A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High- Risk Prostate Cancer
Glenn Bauman et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer
Zaker Rana et al.
RADIATION ONCOLOGY (2015)
Stereotactic ablative radiotherapy with CyberKnife in the treatment of locally advanced prostate cancer: preliminary results
Chao-Yueh Fan et al.
TUMORI JOURNAL (2015)
Stereotactic ablative radiotherapy with CyberKnife in the treatment of locally advanced prostate cancer: preliminary results
Chao-Yueh Fan et al.
TUMORI JOURNAL (2015)
Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry
Joanne Davis et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2015)
Prostate Stereotactic Body Radiotherapy - First UK Experience
A. C. Tree et al.
CLINICAL ONCOLOGY (2014)
Hypofractioned radiotherapy in prostate cancer: is it the next step?
Fabio Ynoe de Moraes et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Stereotactic Body Radiation Therapy for Prostate Cancer Patients with Old Age or Medical Comorbidity A 5-year Follow-Up of an Investigational Study
Sea-Won Lee et al.
MEDICINE (2014)
Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study
Alan Katz et al.
RADIATION ONCOLOGY (2014)
Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm3)
Einsley Janowski et al.
RADIATION ONCOLOGY (2014)
Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival
Wilma D. Heemsbergen et al.
RADIOTHERAPY AND ONCOLOGY (2014)
Evolution of hypofractionated accelerated radiotherapy for prostate cancer the Sunnybrook experience
Hima Bindu Musunuru et al.
FRONTIERS IN ONCOLOGY (2014)
Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study
Alan Jay Katz et al.
FRONTIERS IN ONCOLOGY (2014)
Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience
Leonard N. Chen et al.
RADIATION ONCOLOGY (2013)
Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King et al.
RADIOTHERAPY AND ONCOLOGY (2013)
A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy
Giampaolo Bolzicco et al.
BMC UROLOGY (2013)
Stereotactic body radiation therapy for the primary treatment of localized prostate cancer
Caspian Oliai et al.
JOURNAL OF RADIATION ONCOLOGY (2013)
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
Padraig Warde et al.
LANCET (2011)
Image-guided stereotactic body radiation therapy for localized prostate cancer
Jin-Kyu Kang et al.
TUMORI JOURNAL (2011)
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
Michel Bolla et al.
LANCET ONCOLOGY (2010)
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
Anders Widmark et al.
LANCET (2009)
An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions
Colleen A. Lawton et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
David P. Dearnaley et al.
LANCET ONCOLOGY (2007)
Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy
STH Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate - A randomized controlled trial
AL Zietman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Share Paper
